QUECTEL-WIRELESS
10.11.2022 10:01:40 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, announces that its industrial-grade 5G NR module RG500L-EU has gained GCF certification for operating on global 5G NR networks. The GCF certification means that the RG500L-EU module can help customers to efficiently deploy their 5G high-speed IoT devices worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109006142/en/
Quectel, a global IoT solutions provider, announces GCF certification for it's industrial-grade 5G NR module RG500L-EU (Photo: Business Wire)
Based upon the MediaTek T750 platform, the RG500L-EU integrates a 5G NR FR1 modem and a quadcore Arm Cortex-A55 processor. By leveraging the powerful CPU performance of the T750 chipset, customer devices can improve their device processing performance as well as enable significant cost optimization.
“The global certification by the GCF confirms our commitment to provide our customers with best-in-class IoT solutions, no matter where they are in the world,” said Dominikus Hierl, Senior Vice President Sales EMEA. “Quectel continues to drive IoT innovation, providing the very best in 5G modules and delivering the innovation our customers have come to expect in order to develop their 5G IoT applications.”
The module supports dual carrier aggregation (2CC CA) at 200MHz frequency band. This capability to combine available 5G spectrum assets can greatly improve signal coverage and transmission rates. Additionally, the RG500L-EU module can achieve a peak downlink rate of 4.67Gbps and a peak uplink rate of 1.25Gbps, bringing smooth and super-fast 5G speed experience to end users.
The RG500L-EU supports EasyMesh™ and WPA3 R3 encryption protocol, enabling IoT devices with more stable, cost-efficient and secure wireless connections. The module also offers flexible Wi-Fi configuration combinations, including single 5G 2x2 + 2.4G 2x2 dual-band, single 5G 4x4 + single 2.4G 4x4 dual-band, as well as single 5G 4x4 (5G high frequency band) + single 5G 4x4 (5G low frequency band) + single 2.4G 4x4 tri-band.
Featuring a compact design and low power consumption, the RG500L-EU can help customers to reduce time-consuming procedures including fixed network and equipment installation. Its rich peripheral interfaces including SGMII, PCIe and PCM give customers maximum flexibility in their IoT solution designs. In combination with Quectel’s unique QuecOpen platform, the RG500L-EU also improves customer terminal development efficiency and accelerates their time-to-market.
The RG500L-EU adopts an 8-antenna solution with four 2.7GHz antennas and four n77/n78 dedicated antennas to provide terminals with stronger and more stable signals as well as higher peak download rates. The module can additionally provide high gain antenna covering n78 band to help with signal reception.
In addition to the GCF certification, Quectel's 5G module RG500L-EU has also passed CE approval for the EU market as well as RCM approval for the Australian region. In the above areas, Quectel’s RG500L-EU module has already been chosen by customers to develop a variety of terminals including mobile hotspots, customer premise equipment (CPE), outdoor unit (ODU) and other 5G converged gateways and industrial gateways, which have been deployed in areas like industrial monitoring, remote collaboration, video conferencing, telemedicine, online education and many other fields.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109006142/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom